natgillin/translations-raw huggingface dataset:
Levodopa competes with certain amino acids for transport, therefore high protein meals may impair the absorption of levodopa. 
Levodopa se natječe s nekim aminokiselinama za prijenos, stoga visokoproteinski obroci mogu umanjiti apsorpciju levodope.
Management of acute overdose with levodopa/DDC preparations is the same as management of acute overdose with levodopa. 
Zbrinjavanje akutnog predoziranja preparatima levodope/ DDC inhibitora jednako je zbrinjavanju akutnog predoziranja levodopom.
b) Combined term that includes atrial fibrillation, atrial flutter, atrioventricular block, bundle branch block, sick sinus syndrome, bradycardia, and tachycardia 
b) Kombinirani termin koji uključuje fibrilaciju atrija, undulaciju atrija, atrioventrikularni blok, blok grane, sindrom bolesnog sinusa,
Your doctor will tell you exactly how many capsules of Numient to take each day If you have never had levodopa before, the usual starting dose for Numient is one 95 mg capsule three times a day for three days. 
Ako nikada prije niste uzimali levodopu, uobičajena početna doza za Numient je jedna kapsula od 95 mg tri puta dnevno kroz tri dana.
The bioavailability of carbidopa from this medicinal product relative to immediate release levodopa and carbidopa tablets was approximately 50%. 
Bioraspoloživost karbidope iz tog lijeka u odnosu na tablete levodope/karbidope s trenutnim oslobađanjem bila je otprilike 50 %.
Modified-release levodopa/carbidopa may be used together with other medicinal products for the treatment of Parkinson's disease. 
Levodopa/karbidopa s prilagođenim oslobađanjem se smije primjenjivati zajedno s drugim lijekovima za liječenje Parkinsonove bolesti.
A symptom complex resembling neuroleptic malignant syndrome and rhabdomyolysis may occur with levodopa/carbidopa medicinal products, although no cases have been identified in clinical studies with Numient. 
Kompleks simptoma koji nalikuju neuroleptičkom malignom sindromu i rabdomiolizi mogu se pojaviti kod primjene lijekova koji sadrže levodopu/karbidopu, iako takvi slučajevi nisu ustanovljeni u kliničkim ispitivanjima s Numientom.
Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating, and dopamine dysregulation syndrome can occur in patients treated with dopamine agonists and/or other dopaminergic treatments containing levodopa. 
Bolesnici i njegovatelji moraju biti svjesni da simptomi ponašanja poremećaja kontrole impulsa uključuju patološko kockanje, povećani libido, hiperseksualnost, kompulzivno trošenje ili kupovanje, prejedanje i kompulzivno jedenje, a može se pojaviti i sindrom poremećene regulacije dopamina u bolesnika liječenih agonistima dopamina i/ili drugim dopaminergičkim liječenjima koja sadrže levodopu.
Orthostatic hypotension (see section 4.4 and 4.9), hypertension (see section 
Krvožilni poremećaji ortostatska hipotenzija (vidjeti dijelove 4.4 i 4.9), hipertenzija (vidjeti dio 4.5)
Alternatively, if you have difficulty swallowing a capsule, this medicine may be administered by carefully opening the capsule and sprinkling the entire contents on a small amount (e.g., 2 tablespoons) of soft food such as apple sauce, yoghurt, or pudding. 
Ako imate poteškoća pri gutanju kapsule, ovaj se lijek može primjenjivati pažljivim otvaranjem kapsule i posipanjem čitavog sadržaja na malu količinu (npr. 2 velike žlice) mekane hrane kao što je kaša od jabuka, jogurt ili puding.
Change from baseline at week 30 (or at early termination)c) 
Promjena od početne vrijednosti u 30. tjednu (ili kod ranog prekida)
There is a recognized drug-drug interaction of levodopa with type B MAO inhibitors which potentiates the effects of levodopa. 
Potvrđena je reakcija između lijeka levodope i MAO inhibitora tip B što naglašava učinke levodope.
The safety and efficacy of Numient in patients under 18 years of age have not been studied 
Sigurnost i djelotvornost Numienta u bolesnika mlađih od 18 godina nije ispitivana.
The other ingredients are cellulose, microcrystalline, mannitol, tartaric acid, ethylcellulose, hypromellose, sodium starch glycolate, sodium laurilsulfate, povidone, talc, methacrylic acidmethyl methacrylate copolymers (1:1), methacrylic acid - methyl methacrylate copolymers (1:2), triethyl citrate, croscarmellose sodium and magnesium stearate 
Ostali sastojci su mikrokristalična celuloza, manitol, tartarična kiselina, etilceluloza, hipromeloza, natrijev škrobni glikolat, natrijev lauril sulfat, povidon, talk, metakrilna kiselinametil metakrilat kopolimeri (1:1), metakrilna kiselina - metil metakrilat kopolimeri (1:2), trietil citrat, umrežena karmelozanatrij i magnezijev stearat
When converting patients from levodopa/DDC inhibitor medicinal products to Numient, the dose should be adjusted to maintain sufficient symptomatic control. 
Kada bolesnici prelaze s lijekova koji sadrže levodopu/DDC inhibitor na Numient, potrebno je prilagoditi dozu kako bi se održala dovoljna kontrola simptoma.
The bioavailability of levodopa from Numient in patients was approximately 70% relative to immediate release levodopa/carbidopa. 
Bioraspoloživost levodope iz Numienta u bolesnika bila je otprilike 70 % u odnosu na levodopu/karbidopu s trenutnim oslobađanjem.
400 to 549 
400 do 549
For patients currently treated with other levodopa/DDC inhibitor modified-release medicinal products, limited information regarding conversion to Numient is available. 
Za bolesnike koji se trenutno liječe drugim lijekovima s prilagođenim oslobađanjem koji sadrže levodopu/DDC inhibitor, dostupne su ograničene informacije koje se odnose na prelazak na Numient.
Decreased appetite, weight increase 
Poremećaji metabolizma i prehrane smanjenje težine smanjen apetit, povećanje težine
Initial dose and titration in levodopa-naïve patients 
Početna doza i titracija u bolesnika koji nisu liječeni levodopom
Levodopa/carbidopa should be administered cautiously to patients with ischemic heart disease, severe cardiovascular or pulmonary disease, bronchial asthma, renal, hepatic or endocrine disease, or history of peptic ulcer disease (because of the possibility of upper gastro-intestinal haemorrhage) and a history of convulsions. 
Levodopu/karbidopu treba primjenjivati uz oprez u bolesnika s ishemijskom bolešću srca, teškom kardiovaskularnom ili plućnom bolešću, bronhalnom astmom, bubrežnom, jetrenom ili endokrinom bolešću, kao i u bolesnika s anamnezom peptičkog ulkusa (zbog mogućnosti hemoragije iz gornjeg gastrointestinalnog trakta) i konvulzija.
In vivo, co-administration of Numient with up to 40% volume-to-volume (v/v) alcohol did not result in dosedumping of levodopa or carbidopa. 
In vivo istodobna primjena Numienta s alkoholom do 40 % volumenske koncentracije nije dovela do nakupljanja doze levodope ili karbidope.
Phaeochromocytoma. 
Feokromocitom.
The starting dose is one capsule containing 95 mg of levodopa and 23.75 mg carbidopa three times daily (TID) for the first three days; this may be increased to a dose of one modified-release hard capsule containing 145 mg of levodopa and 36.25 mg carbidopa three times daily from Day 4 of treatment. 
Početna doza je jedna kapsula koja sadrži 95 mg levodope i 23,75 mg karbidope tri puta dnevno (TID) u prva tri dana; može se povećati na dozu od jedne tvrde kapsule s prilagođenim oslobađanjem koja sadrži 145 mg levodope i 36,25 mg karbidope tri puta dnevno od 4. dana liječenja.
The ingredients in the hard capsule shell are indigo carmine (E132) lake, yellow iron oxide (E172), titanium dioxide (E171) and gelatine 
Sastojci u ovojnici tvrde kapsule su indigo karmin (E132) lake, žuti željezov oksid (E172), titanijev dioksid (E171) i želatina
If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 
U slučaju bilo kakvih dodatnih pitanja u vezi s primjenom ovog lijeka, obratite se svom liječniku ili ljekarniku.
Levodopa-naïve patients with Parkinson's disease APEX-PD 
Bolesnici s Parkinsonovom bolešću koji nisu liječeni levodopom APEX-PD
Carbidopa inhibits decarboxylation of peripheral levodopa. 
Karbidopa inhibira dekarboksilaciju periferne levodope.
The dose of the modified-release levodopa/carbidopa capsule medicinal product may need to be decreased with concomitant use of COMT inhibitors. 
Dozu kapsule lijeka s prilagođenim oslobađanjem levodope/karbidope može biti potrebno smanjiti prilikom istodobne primjene inhibitora COMT-a.
Table 4: Mean change from baseline in UPDRS Part II plus Part III score at week 30 (or at early termination) in levodopa naïve patients with Parkinson's disease (APEX-PD) 
Tablica 4: Srednja vrijednost promjena od početne vrijednosti u rezultatu dijela II i dijela III UPDRSa u 30. tjednu (ili kod ranog prekida) u bolesnika oboljelih od Parkinsonove bolesti koji nisu liječeni levodopom (APEX-PD)
Adverse reactions are listed below by system organ class (SOC) and frequency (Table 3). 
U nastavku su navedene nuspojave prema klasifikaciji organskih sustava i učestalosti (Tablica 3).
If any of this happens, contact your doctor immediately an eye condition called chronic wide angle glaucoma, because your dose may need to be adjusted and the pressure in your eyes may need to be monitored melanoma or suspicious skin lesion a heart attack, heart beat problems, circulation or breathing problems kidney or liver problems an ulcer in your gut (called ‘duodenal' or ‘peptic ulcer') an endocrine (hormone) disease bronchial asthma obsessive behaviour(s) convulsions low blood pressure or feeling dizzy when getting up new or increased abnormal body movements (dyskinesias) 
Ako se dogodi bilo što od toga, odmah se obratite svojem liječniku bolest oka koja se naziva kronični glaukom širokog kuta, budući da tada Vašu dozu možda treba prilagoditi i pratiti očni tlak melanom ili sumnjive kožne lezije srčani udar, probleme s otkucajima srca, cirkulacijom ili disanjem bubrežne ili jetrene probleme vrijed (čir) u crijevima (koji se naziva „vrijed na dvanaesniku“ ili „peptički ulkus“) endokrinu (hormonalnu) bolest bronhalnu astmu opsesivno(a) ponašanje(a) konvulzije snižen krvni tlak ili osjećaj omaglice kod ustajanja nove ili pojačane abnormalne pokrete tijela (diskinezije)
Numient contains two different medicines called levodopa and carbidopa in one hard capsule. 
Numient sadrži dva različita lijeka koji se nazivaju levodopa i karbidopa u jednoj tvrdoj kapsuli. levodopa se u Vašem mozgu pretvara u tvar koja se naziva „dopamin“.
Following administration of the modified-release hard capsule contents sprinkled over a small quantity (e.g., 2 tablespoons) of soft food such as apple sauce, yoghurt, or pudding, the rate and extent of absorption of levodopa was similar to that observed in the fasted state. 
Nakon primjene sadržaja tvrde kapsule s prilagođenim oslobađanjem posutog na malu količinu (npr. 2 velike žlice) mekane hrane kao što je kaša od jabuke, jogurt ili puding, brzina i opseg apsorpcije levodope bili su slični vrijednostima zapaženima natašte.
Administration with a high-fat, high-calorie meal delays levodopa absorption by up to 2 hours (see section 4.2). 
Primjena s obrokom s visokim udjelom masti i kalorija odgađa apsorpciju levodope do 2 sata (vidjeti dio 4.2).
Patients taking these medicinal products together with levodopa/carbidopa should be monitored carefully for loss of therapeutic response. 
Bolesnike koji uzimaju te lijekove zajedno s levodopom/karbidopom mora se pažljivo pratiti zbog gubitka terapijskog odgovora.
Numient has not been studied in patients with hepatic impairment. 
Numient nije ispitivan u bolesnika s oštećenjem jetre.
Indigo carmine (E132), lake Yellow iron oxide (E172) Titanium dioxide (E171) Gelatine 
Ovojnica kapsule indigo karmin (E132), lake žuti željezov oksid (E172) titanijev dioksid (E171) želatina
Therefore, Numient should not be taken at the same time as high protein meals. 
Zato Numient ne treba uzimati istodobno s obrocima koji sadrže visok udio bjelančevina.
If general anaesthesia is required, the modified-release levodopa/carbidopa capsule medicinal product may be continued as long as the patient is permitted to take oral medicinal products. 
Ako je potrebna opća anestezija, uzimanje kapsule lijeka s prilagođenim oslobađanjem koja sadrži levodopu/karbidopu može se nastaviti sve dok je bolesniku dozvoljeno uzimati lijekove kroz usta.
Therefore, patients must be monitored carefully when the dose of levodopa/carbidopa is reduced abruptly or discontinued, especially if the patient is receiving antipsychotics (see section 4.2). 
Stoga bolesnike treba pažljivo pratiti kada se doza levodope/karbidope naglo smanjuje ili prekida, naročito ako bolesnik prima antipsihotike (vidjeti dio
Sporadic cases of a symptom complex resembling neuroleptic malignant syndrome (NMS) have been associated with dose reductions and withdrawal of levodopa/carbidopa containing medicinal products. 
Sporadični slučajevi kompleksa simptoma nalik neuroleptičkom malignom sindromu (NMS) povezuju se sa smanjenjem doze i povlačenjem lijekova koji sadrže levodopu/karbidopu.
The ingredients in the ink are SB-6018 blue ink, shellac (E904), propylene glycol, and indigo carmine (E132) lake 
Sastojci u tinti su plava tinta SB-6018, šelak (E904), propilen glikol i indigo karmin (E132) lake
Total daily dose of levodopa in immediate release levodopa/DDC inhibitor (mg) 
Ukupna dnevna doza levodope u lijeku s trenutnim oslobađanjem koji sadrži levodopu/inhibitor DDC (mg)
pruritus (see section 4.3) purpura, urticaria (see section 4.3), hair loss, exanthema, dark sweat 
Henoch-Schönleinova purpura, urtikarija (vidjeti dio 4.3), gubitak kose, egzantem, taman znoj
Melanoma (see section 
melanom (vidjeti dio 4.4)
Products containing ferrous sulphate should be administered separately from levodopa/carbidopa, with the longest possible time interval between administrations (see section 4.5). 
Proizvodi koji sadrže željezov sulfat moraju se primijeniti odvojeno od levodope/karbidope, s najduljim mogućim vremenskim razmakom između primjena (vidjeti dio 4.5).
Patients taking these medicinal products with levodopa/carbidopa should be carefully monitored for loss of therapeutic response. 
Bolesnike koji uzimaju ove lijekove zajedno s levodopom/karbidopom mora se pažljivo pratiti zbog gubitka terapijskog odgovora.
Abbreviations: CGI-C: clinical global impression of change from baseline; CI: confidence interval; IR: immediate release; LCE: Levodopa/Carbidopa/Entacapone; L-dopa†: Levodopa/Carbidopa; LS: least squares; PD: Parkinson's disease; SD: standard deviation; N/A: not available; hrs: hours; yrs: years. 
Clinical Global Impression of Change from Baseline); CI: interval pouzdanosti: IR: trenutno otpuštanje; LCE: levodopa/karbidopa/entakapon; L-dopa†: Levodopa/karbidopa; LS: najmanji kvadrati; PD: Parkinsonova bolest; SD: standardna devijacija; N/A: nije raspoloživo; *U ispitivanju ADVANCE-PD korišten je model Analize kovarijance (ANCOVA) za kraj ispitivanja s liječenjem i centrima kao glavnim učincima, a rok interakcije za liječenje po centru i početnoj vrijednosti kao kovarijancom.
This may cause difficulties in breathing or swallowing Your muscles get very rigid or jerk violently, you get tremors, agitation, confusion, fever, rapid pulse, or wide fluctuations in your blood pressure. 
Vaši mišići postanu jako ukočeni ili se snažno trzaju, pojavilo se nevoljno drhtanje, uznemirenost, smetenost, vrućica, ubrzani puls ili izrazite promjene krvnog tlaka.
No dose adjustment of the modified-release levodopa/carbidopa medicinal product is required for elderly patients. 
Nije potrebna prilagodba doze lijeka levodopa/karbidopa s prilagođenim oslobađanjem u starijih bolesnika.
The following side effects have also been reported but the chance that they will occur is unknown: Low blood cell counts (white blood cells, platelets) Drug abuse of certain medicines used to treat Parkinson's Disease Suicide attempt, feeling disoriented, increased sexual feelings Severe prolonged abnormal eye movements, Horner's Syndrome (drooping eyelid, small pupil and decreased sweating on one side of the face), eyelid twitching Abnormal breathing pattern 
Sljedeće nuspojave također su prijavljene, ali nije poznata mogućnost njihovog nastanka: nizak broj krvnih stanica (bijele krvne stanice, trombociti) zlouporaba nekih lijekova za liječenje Parkinsonove bolesti pokušaj samoubojstva, osjećaj dezorijentiranosti, povećani seksualni osjećaji teški produljeni abnormalni pokreti očiju, Hornerov sindrom (spušteni kapak, uska zjenica i smanjeno znojenje na jednoj strani lica), trzanje kapka abnormalan obrazac disanja pretjerano stvaranje sline ili tamno obojena slina, škrgutanje zubima, štucanje gubitak kose, osip (uključujući težak osip pod nazivom Henoch-Schönleinova purpura), tamno obojeni znoj
Modified-release levodopa/carbidopa should be administered cautiously to patients with severe renal impairment (see section 4.2). 
Levodopa/karbidopa s prilagođenim oslobađanjem mora se primjenjivati uz oprez u bolesnika s teškim oštećenjem bubrega (vidjeti dio 4.2).
Patients were not allowed to receive supplemental levodopa or catechol-O-methyl transferase (COMT) inhibitors. 
Bolesnicima nije dozvoljeno dodatno primanje levodope ili inhibitora katehol-O-metil transferaze (COMT).
750 to 949 
750 do 949
The effect of co-administration of this modified-release levodopa/carbidopa capsule product and COMT inhibitors such as entacapone has not been studied. 
Učinak istodobne primjene ove kapsule s prilagođenim oslobađanjem levodope/karbidope i inhibitora COMT-a kao što je entakapon nije ispitivan.
When patients are initially converted from immediate release levodopa/DDC inhibitor medicinal products to Numient, the dosing conversion guidelines provided in Table 1 are recommended for initial dosing. 
Kada bolesnici u početku prelaze s lijekova s trenutnim oslobađanjem koji sadrže levodopu/DDC inhibitor na Numient, za početno doziranje preporučene su smjernice za pretvaranje doze navedene u Tablici 1.
Swallow the medicine/food mixture completely and immediately without chewing and do not store for future use Take the capsules at regular time intervals according to your doctor's instructions Do not change the times at which you take your capsules or take any other medicines for Parkinson's disease without first consulting your doctor. 
Progutajte mješavinu lijek/hrana u cijelosti i odmah, bez žvakanja, i ne ostavljajte za kasniju uporabu Uzmite kapsule u redovnim vremenskim intervalima prema uputama Vašeg liječnika
Each capsule contains 95 mg of levodopa and 23.75 mg of carbidopa (as monohydrate). 
Svaka kapsula sadrži 95 mg levodope i 23,75 mg karbidope (u obliku hidrata).
Renal excretion of intact levodopa accounts for only about 10% of clearance. 
Izlučivanje nepromijenjene levodope putem bubrega iznosi samo oko 10 % klirensa.
Patients were not allowed to receive supplemental levodopa/carbidopa or catechol-O-methyl transferase (COMT) inhibitor medicinal products during the trial. 
Bolesnicima nije dozvoljeno dodatno primanje lijekova koji sadrže levodopu/karbidopu ili inhibitore katehol-O-metil transferaze (COMT) tijekom ispitivanja.
Ink 
Tinta
The dosing frequency may be changed from three times a day to a maximum of five times a day if sufficient symptomatic control is not observed. 
Ako nije opažena dovoljna kontrola simptoma, učestalost doziranja može se promijeniti s tri puta dnevno na najviše pet puta dnevno.
Modified-release hard capsule 
Tvrde kapsule s prilagođenim oslobađanjem
Musculoskeletal and connective tissue disorders 
Poremećaji mišićno-koštanog sustava i vezivnog tkiva spazmi mišića
550 to 749 
550 do 749
Following administration of the modified-release hard capsule contents sprinkled over a small quantity of soft food such as apple sauce, the rate and extent of absorption of levodopa was similar to that observed in the fasted state. 
Nakon primjene sadržaja tvrde kapsule s prilagođenim oslobađanjem posutog na malu količinu mekane hrane kao što je kaša od jabuke, stopa i opseg apsorpcije levodope slični su onima opaženim natašte.
Sporadic cases of a symptom complex resembling NMS have been reported in association with dose reductions or withdrawal of levodopa/carbidopa medicinal products. 
Sporadični slučajevi kompleksa simptoma nalik na NMS prijavljeni su u vezi sa smanjenjima doze ili povlačenjem lijekova koji sadrže levodopu/karbidopu.
Table 1: Guidelines for initial conversion from immediate release (IR) levodopa/DDC inhibitor medicinal products to Numient in Parkinson's disease patients. 
Tablica 1: Smjernice za početni prelazak s lijeka s trenutnim oslobađanjem (IR, engl. immediate release) koji sadrži levodopu/DDC inhibitor na Numient u oboljelih od Parkinsonove bolesti.
3 hard capsules 145 mg/36.25 mg TID 
3 tvrde kapsule od 145 mg/36,25 mg TID
Products containing ferrous sulphate and levodopa/carbidopa should be administered separately with the longest possible time interval between administrations (see section 4.2). 
Proizvodi koji sadrže željezov sulfat moraju se primjenjivati odvojeno od levodope/karbidope, s najduljim mogućim vremenskim razmakom između primjena (vidjeti dio 4.2).
Inability to resist the impulse to perform an action that could be harmful, which may include: Strong impulse to gamble excessively despite serious personal or family consequences Altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive 
Možete također imati sljedeće nuspojave: - Nemogućnost odupiranja impulsu (porivu) za obavljanje određene radnje koja može biti štetna, što može uključivati: snažan impuls za prekomjernim kockanjem usprkos teškim osobnim ili obiteljskim posljedicama promijenjena ili pojačana spolna želja i ponašanje koje značajno zabrinjava Vas i druge, npr. pojačan seksualni nagon nekontrolirano prekomjerno kupovanje ili trošenje neumjerenost u jelu (uzimanje velikih količina hrane u kratkom vremenskom razdoblju) ili kompulzivno (prisilno) uzimanje hrane (uzimanje hrane u količini većoj nego što je uobičajeno i više od količine koja zadovoljava glad)
Periodic evaluation of hepatic, haematopoietic, cardiovascular and renal function is recommended during extended therapy. 
Tijekom produljene terapije preporučuje se povremena procjena jetrene, hematopoetske, kardiovaskularne i bubrežne funkcije.
subcutaneous tissue disorders hyperhidrosis, rash (see section 4.3) 
Poremećaji kože i potkožnog tkiva navale vrućine, hiperhidroza, osip (vidjeti dio 4.3)
3 hard capsules 245 mg/61.25 mg TID 4 hard capsules 245 mg/61.25 mg TID 
3 tvrde kapsule 245 mg/61,25 mg TID 4 tvrde kapsule 245 mg/61,25 mg TID
Bleeding in your stomach or intestines which may be seen as blood in your faeces or darkened faeces An allergic reaction, the signs of which may include hives (nettle rash), itching, rash, swelling of your face, lips, tongue or throat. 
Ako imate bilo koji od sljedećih simptoma tijekom liječenja Numientom, odmah kontaktirajte svog liječnika: krvarenje u želucu ili crijevima koje se može vidjeti kao krv u stolici ili tamna stolica alergijsku reakciju čiji znakovi uključuju koprivnjaču (urtikariju), svrbež, osip, oticanje lica, usana, jezika ili grla.
Oculogyric crises, activation of latent Horner's syndrome, blepharospasm 
Poremećaji oka zamućen vid, diplopija, midrijaza okulogirna kriza, aktivacija latentnog Hornerovog sindroma, blefarospazam
Numient has not been studied in patients with renal impairment. 
Numient nije ispitivan u bolesnika s oštećenjem bubrega.
Cardiac rhythm disordersb) (see section 
Srčani poremećaji poremećaji srčanog ritmab) (vidjeti dio palpitacije
25 modified-release hard capsules 100 modified-release hard capsules 240 modified-release hard capsules 
OBLIK I SADRŽAJ 25 tvrdih kapsula s prilagođenim oslobađanjem 100 tvrdih kapsula s prilagođenim oslobađanjem 240 tvrdih kapsula s prilagođenim oslobađanjem
2 hard capsules 245 mg/61.25 mg TID 
2 tvrde kapsule 245 mg/61,25 mg TID
CNS effects and mental disturbances 
Učinci na središnji živčani sustav (SŽS) i mentalni poremećaji